Oncology

Methotrexate and cyclophosphamide burn excessive dietary fat.

Aurintricarboxylic acid blocks the spread of glioblastoma.

Plant compound inhibits the metastasis of aggressive breast cancer in mice.

Markers identify patients who benefit from new and more aggressive prostate cancer treatments.

Small cell tumors respond differently to treatment.

Conflicts of interest among committee members who set hepatitis C treatment guidelines may influence decision-making.

Cancer screenings do not reduce the incidence of advanced tumors.

Top news of the day from across the health care landscape.

Physical activity can help overcome comorbidities associated with aromatase inhibitor treatment for breast cancer.

Antibody-based therapy may be a novel addition to immunotherapies for breast cancer, lung cancer, and colon cancer.

Cognitive impairment more prevalent in patients with HIV coinfection than in those with hepatitis C infection alone.

Top news of the day from across the health care landscape.

Top news of the week in oncology and cancer drug development.

A $450,000 research grant is targeting triple negative breast cancer and HER2-positive breast cancer.

Level of emotional distress after prostate cancer diagnosis increases likelihood of choosing surgery over active surveillance.

Cancer cells more prone to damage and death from high amounts of hydrogen peroxide.

Study provides better understanding of why some cancers are resistant to therapy.

Glecaprevir is a NS3/4A protease inhibitor and pibrentasvir is a NS5A inhibitor for hepatitis C patients without cirrhosis.

Glecaprevir/pibrentasvir is indicated as an eight-week treatment for hepatitis C among patients without cirrhosis.

Histone H3 protein is abnormal or incorrectly modified in 15% of patients with head and neck cancer.

High consumption of grilled, barbequed, or smoked meats may increase morality risk in breast cancer survivors.

Study confirms safety and efficacy of Lu-177-PSMA-17 radioligand therapy for metastatic castration-resistant prostate cancer.

A drug developed to treat cardiogenic shock may treat patients with triple negative breast cancer.

BRCA2-inherited prostate cancers are predisposed to turn treatment resistant.

A personalized vaccine may effectively treat HER2-postive breast cancer.

Capsaicin derived from chili peppers shows promise on cultured triple-negative breast cancer cells.

Capsaicin could activate a receptor that prevents metastasis.

Driven by the graying of America, more than 75% of all newly diagnosed cancers occur in people aged 55 or older. Oncology—and oncology pharmacists—are changing hats swiftly.